January 22, 2022 : Issue #1184

TOP STORIES — Diabetes News and Research

How Low Should Blood Pressure Targets Go?

Ineffective Cholesterol Treatment in Type 2 Patients

Barriers to Weight Loss and Diet After Gestational Diabetes

Cardiovascular Benefits of SGLT-2 Inhibitors

How To Address Dexamethasone-Induced Hyperglycemia for Patients with Covid-19

Evaluation of CVD/CKD Risks in Patients with Type 2 Diabetes

There are a lot of theories on the internet concerning what you are doing to your body if you take a statin. Unfortunately, these stories do not have a shred of evidence to prove what the writer is saying is actually true.

Unfortunately, many of our patients have more faith in Dr. Google than real medical professionals. I believe part of the reason is from the amount of data a company has to share to prove to the FDA their medication is legitimate. This versus the small amount for a product that someone touts on a TV commercial.

By the time you hear all those claims you are afraid to pick the first statin. But is that good for you if you have diabetes? This week our intern, Elmoataz Elmamoun, PharmD Candidate, 2022, South College School of Pharmacy, has combined lots of research on statins and adherence and how it affects patients with diabetes.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Should current guidelines lower the blood pressure treatment threshold for increased prevention of CVD?

Addressing the gaps in lipoprotein cholesterol (LDL-C) control and statin prescribing among patients with type 2 diabetes.

No differences in the barriers to weight loss and weight loss success were observed between the intermittent (IER) and continuous (CER) dieters.

In addition to clinical trials, does data from a meta-analysis of retrospective cohort studies support the benefits of SGLT-2 inhibitors?

Can we reduce mortality with patients with Covid-19 by controlling blood glucose?

Despite being on first-line oral anti-diabetic drug therapy, the risk of developing CVD/CKD in patients with type 2 diabetes remains high.

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter:

Idris Aderoju, PharmD Candidate, Florida A&M College of Pharmacy

Elmoataz Elmamoun, PharmD Candidate, 2022, South College School of Pharmacy

Erica Hicks, PharmD Candidate 2022, South College School of Pharmacy

Kmeone Kingdom, MPH, PharmD Candidate, South College School of Pharmacy

Ding Nguyen, PharmD Candidate, University of South Florida Taneja College of Pharmacy

Your Friends in Diabetes Care
Steve and Dave

Diabetes In Control
www.diabetesincontrol.com